| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A further face of the partial thromboplastin time APTT
|
TOH, C.H.
|
|
|
3 |
5 |
p. 1107-1108
|
artikel
|
| 2 |
Altered cytoskeleton organization in platelets from patients with MYH9‐related disease
|
CANOBBIO, I.
|
|
|
3 |
5 |
p. 1026-1035
|
artikel
|
| 3 |
A model‐based algorithm for the monitoring of long‐term anticoagulation therapy
|
PASTERKAMP, E.
|
|
|
3 |
5 |
p. 915-921
|
artikel
|
| 4 |
A monoclonal antibody that inhibits mouse tissue factor function
|
KIRCHHOFER, D.
|
|
|
3 |
5 |
p. 1098-1099
|
artikel
|
| 5 |
Announcements
|
|
|
|
3 |
5 |
p. 1117
|
artikel
|
| 6 |
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) 1 1 The WAPS Investigators are listed in the Appendix.
|
FINAZZI, G.
|
|
|
3 |
5 |
p. 848-853
|
artikel
|
| 7 |
Budd–Chiari syndrome in a paroxysmal nocturnal hemoglobinuria patient with coexistence of factor II and MTHFR mutations
|
SHAMSEDDINE, A.I.
|
|
|
3 |
5 |
p. 1111
|
artikel
|
| 8 |
Cardiovascular and thrombophilic risk factors for idiopathic sudden sensorineural hearing loss
|
MARCUCCI, R.
|
|
|
3 |
5 |
p. 929-934
|
artikel
|
| 9 |
Cell‐derived microparticles contain caspase 3 in vitro and in vivo
|
ABID HUSSEIN, M.N.
|
|
|
3 |
5 |
p. 888-896
|
artikel
|
| 10 |
Cell‐derived microparticles: ‘Miniature envoys with many faces’
|
AHN, Y.S.
|
|
|
3 |
5 |
p. 884-887
|
artikel
|
| 11 |
Cloning, expression and functional characterization of the full‐length murine ADAMTS13
|
BRUNO, K.
|
|
|
3 |
5 |
p. 1064-1073
|
artikel
|
| 12 |
Corrigendum
|
|
|
|
3 |
5 |
p. 1118
|
artikel
|
| 13 |
Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide
|
DEGUCHI, H.
|
|
|
3 |
5 |
p. 935-938
|
artikel
|
| 14 |
Delayed tirofiban‐induced thrombocytopenia: two case reports
|
BOSCO, A.
|
|
|
3 |
5 |
p. 1109-1110
|
artikel
|
| 15 |
Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case–control study
|
DOUKETIS, J.D.
|
|
|
3 |
5 |
p. 943-948
|
artikel
|
| 16 |
Dose–response study of recombinant human soluble thrombomodulin (ART‐123) in the prevention of venous thromboembolism after total hip replacement
|
KEARON, C.
|
|
|
3 |
5 |
p. 962-968
|
artikel
|
| 17 |
Enhanced blood coagulation and fibrinolysis in mice lacking histidine‐rich glycoprotein (HRG)
|
TSUCHIDA‐STRAETEN, N.
|
|
|
3 |
5 |
p. 865-872
|
artikel
|
| 18 |
First isolation of actomyosin from a non‐muscle cell: first isolated platelet protein
|
BETTEX‐GALLAND, M.
|
|
|
3 |
5 |
p. 834-839
|
artikel
|
| 19 |
Forthcoming articles in the june issue
|
|
|
|
3 |
5 |
p. xi-xii
|
artikel
|
| 20 |
Functional analysis of recombinant Bβ15C and Bβ15A fibrinogens demonstrates that Bβ15G residue plays important roles in FPB release and in lateral aggregation of protofibrils
|
HIROTA‐KAWADOBORA, M.
|
|
|
3 |
5 |
p. 983-990
|
artikel
|
| 21 |
Hemostatic abnormalities associated with obesity and the metabolic syndrome
|
REAVEN, G.M.
|
|
|
3 |
5 |
p. 1074-1075
|
artikel
|
| 22 |
Hemostatic abnormalities associated with obesity and the metabolic syndrome
|
BAILEY, C.
|
|
|
3 |
5 |
p. 1083-1085
|
artikel
|
| 23 |
Hemostatic abnormalities associated with obesity and the metabolic syndrome
|
LOWE, G.D.O.
|
|
|
3 |
5 |
p. 1076-1078
|
artikel
|
| 24 |
Hemostatic abnormalities associated with obesity and the metabolic syndrome
|
STRATMANN, B.
|
|
|
3 |
5 |
p. 1078-1080
|
artikel
|
| 25 |
Hemostatic abnormalities associated with obesity and the metabolic syndrome
|
SCOTT, E.M.
|
|
|
3 |
5 |
p. 1075-1076
|
artikel
|
| 26 |
Hemostatic abnormalities associated with obesity and the metabolic syndrome
|
BLANN, A.
|
|
|
3 |
5 |
p. 1080-1082
|
artikel
|
| 27 |
Hemostatic abnormalities associated with obesity and the metabolic syndrome
|
JUHAN‐VAGUE, I.
|
|
|
3 |
5 |
p. 1082-1083
|
artikel
|
| 28 |
High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis
|
HO, W.K.
|
|
|
3 |
5 |
p. 1094-1095
|
artikel
|
| 29 |
HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo‐controlled study in postmenopausal women
|
VOGELVANG, T.E.
|
|
|
3 |
5 |
p. 1090-1092
|
artikel
|
| 30 |
Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII
|
JONES, T.D.
|
|
|
3 |
5 |
p. 991-1000
|
artikel
|
| 31 |
Increased plasminogen activator inhibitor‐1 levels in android obesity: correlation with oxidative stress
|
FERRONI, P.
|
|
|
3 |
5 |
p. 1086-1087
|
artikel
|
| 32 |
In vivo and in vitro analysis of the human tissue‐type plasminogen activator gene promoter in neuroblastomal cell lines: evidence for a functional upstream κB element
|
LUX, W.
|
|
|
3 |
5 |
p. 1009-1017
|
artikel
|
| 33 |
Is citrate deficiency universal?
|
SHANBROM, E.
|
|
|
3 |
5 |
p. 1108-1109
|
artikel
|
| 34 |
Is contrast venography a valid surrogate outcome measure in venous thromboembolism prevention studies?
|
SEGERS, A.E.M.
|
|
|
3 |
5 |
p. 1099-1102
|
artikel
|
| 35 |
Life without histidine‐rich glycoprotein: modulation of the hemostatic balance revisited
|
BORZA, D.‐B.
|
|
|
3 |
5 |
p. 863-864
|
artikel
|
| 36 |
Lipid rafts are required in Gα i signaling downstream of the P2Y12 receptor during ADP‐mediated platelet activation
|
QUINTON, T.M.
|
|
|
3 |
5 |
p. 1036-1041
|
artikel
|
| 37 |
Lupus anticoagulants and anticardiolipin antibodies: personal reminiscences, a little history, and some random thoughts
|
SHAPIRO, S.S.
|
|
|
3 |
5 |
p. 831-833
|
artikel
|
| 38 |
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No
|
KHAMASHTA, M.A.
|
|
|
3 |
5 |
p. 844-845
|
artikel
|
| 39 |
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No
|
RICKLES, F.R.
|
|
|
3 |
5 |
p. 842-843
|
artikel
|
| 40 |
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? Yes
|
SCULLY, M.‐F.
|
|
|
3 |
5 |
p. 840-841
|
artikel
|
| 41 |
Molecular mechanisms of age‐related regulation of genes
|
KURACHI, K.
|
|
|
3 |
5 |
p. 909-914
|
artikel
|
| 42 |
More on: a survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery
|
PERNOD, G.
|
|
|
3 |
5 |
p. 1115-1116
|
artikel
|
| 43 |
More on: fluvastatin inhibits up‐regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells
|
PIERANGELI, S.S.
|
|
|
3 |
5 |
p. 1112-1113
|
artikel
|
| 44 |
More on: the early discoveries of collagen–platelet interaction and studies on its role in hemostatic plug formation
|
BOUNAMEAUX, H.
|
|
|
3 |
5 |
p. 1116
|
artikel
|
| 45 |
More on: tissue factor in neutrophils
|
MAUGERI, N.
|
|
|
3 |
5 |
p. 1114
|
artikel
|
| 46 |
Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions
|
SHIMBO, D.
|
|
|
3 |
5 |
p. 897-908
|
artikel
|
| 47 |
Oral anticoagulation for the antiphospholipid antibody syndrome: can we now say less is more?
|
ANDERSON, D.R.
|
|
|
3 |
5 |
p. 846-847
|
artikel
|
| 48 |
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long‐term recurrence
|
PALARETI, G.
|
|
|
3 |
5 |
p. 955-961
|
artikel
|
| 49 |
Post‐transcriptional regulation of plasminogen activator inhibitor‐1 by intracellular iron in cultured human lung fibroblasts—interaction of an 81‐kDa nuclear protein with the 3′‐UTR
|
RADHA, K.S.
|
|
|
3 |
5 |
p. 1001-1008
|
artikel
|
| 50 |
Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome
|
VAN DONGEN, C.J.J.
|
|
|
3 |
5 |
p. 939-942
|
artikel
|
| 51 |
Risk of pregnancy‐associated recurrent venous thromboembolism in women with a history of venous thrombosis
|
PABINGER, I.
|
|
|
3 |
5 |
p. 949-954
|
artikel
|
| 52 |
Safety, pharmacokinetics, and immunogenicity of single‐dose rFXIII administration to healthy volunteers
|
REYNOLDS, T.C.
|
|
|
3 |
5 |
p. 922-928
|
artikel
|
| 53 |
Selective inducible nitric oxide synthase inhibition attenuates organ dysfunction and elevated endothelin levels in LPS‐induced DIC model rats
|
ASAKURA, H.
|
|
|
3 |
5 |
p. 1050-1055
|
artikel
|
| 54 |
Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma
|
ÖHLIN, ANN‐KRISTIN
|
|
|
3 |
5 |
p. 976-982
|
artikel
|
| 55 |
Temporary inferior vena caval filter use in pregnancy
|
CHEUNG, M.C.
|
|
|
3 |
5 |
p. 1096-1097
|
artikel
|
| 56 |
Temporary relief of symptomatic Von Willebrand disease by multiple myeloma
|
AUWERDA, J.J.A.
|
|
|
3 |
5 |
p. 1088-1089
|
artikel
|
| 57 |
The antigenic binding site(s) of antibodies to factor XII associated with the antiphospholipid syndrome
|
HARRIS, S.L.
|
|
|
3 |
5 |
p. 969-975
|
artikel
|
| 58 |
The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE)
|
BARBA, R.
|
|
|
3 |
5 |
p. 856-862
|
artikel
|
| 59 |
The leptin receptor system of human platelets
|
GIANDOMENICO, G.
|
|
|
3 |
5 |
p. 1042-1049
|
artikel
|
| 60 |
The poor quality of streptokinase products in use in developing countries
|
LONGSTAFF, C.
|
|
|
3 |
5 |
p. 1092-1093
|
artikel
|
| 61 |
The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level
|
VOSSEN, C.Y.
|
|
|
3 |
5 |
p. 1102-1103
|
artikel
|
| 62 |
The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury
|
RENCKENS, R.
|
|
|
3 |
5 |
p. 1018-1025
|
artikel
|
| 63 |
The skinny on treatment of venous thromboembolism in obesity
|
SPINLER, S.A.
|
|
|
3 |
5 |
p. 854-855
|
artikel
|
| 64 |
Tissue factor enhances protease‐activated receptor‐2‐mediated factor VIIa cell proliferative properties
|
FAN, L.
|
|
|
3 |
5 |
p. 1056-1063
|
artikel
|
| 65 |
Vitronectin: back into the spotlight
|
PLOW, E.F.
|
|
|
3 |
5 |
p. 873-874
|
artikel
|
| 66 |
Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation
|
REHEMAN, A.
|
|
|
3 |
5 |
p. 875-883
|
artikel
|
| 67 |
Ximelagatran and melagatran vs. low‐molecular‐weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration* * Preliminary results of this analysis were presented at the International Congress of Thrombosis in Ljubljana in June 2004 as an oral communication (OC 065).
|
ZUFFEREY, P.
|
|
|
3 |
5 |
p. 1104-1107
|
artikel
|
Tijdschrift beschrijving